| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 20 May 2025 | 9 May 2025 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve audited financial results for the quarter / year ended on March 31 2025 and to recommend final dividend for the financial year ended on March 31 2025. Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31, 2025 The Board also recommended final dividend of Rs. 11/- (@1100%) per equity share of Re. 1/- each, subject to approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on August 12, 2025. (As Per BSE Announcement Dated on 20.05.2025) | ||
| Board Meeting | 11 Mar 2025 | 11 Mar 2025 |
| Acquisition of shares of Amplitude Surgical SA, France, a listed entity | ||
| Board Meeting | 5 Feb 2025 | 21 Jan 2025 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2025 inter alia to consider and approve unaudited financial results of the Company for the quarter / nine months ended on December 31 2024. Unaudited financial results for the quarter / nine months ended on December 31, 2024 (As Per BSE Announcement Dated on: 05/02/2025) | ||
| Board Meeting | 27 Dec 2024 | 27 Dec 2024 |
| Update on acquisition of a business | ||
| Board Meeting | 12 Nov 2024 | 30 Oct 2024 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2024. Unaudited financial results for the quarter and half year ended on September 30, 2024 Unaudited financial results for the quarter and half year ended on September 30, 2024 (As Per BSE Announcement Dated on 12.11.2024) | ||
| Board Meeting | 9 Aug 2024 | 18 Jul 2024 |
| Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2024. Unaudited Financial results for the quarter ended June 30, 2024 (As Per BSE Announcement dated on 09.08.2024) | ||
The acquisition is priced at $7.50 per share and will be completed in cash within 60 days, subject to regulatory approvals
It provides benefits such as faster approval, priority review and a more open line of communication with the F.D.A.
They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.
Consolidated revenue for the March quarter rose 18% YoY to ₹6,528 crore.
The medication is also prescribed to lower the risk of another heart attack in individuals with a past history of myocardial infarction and hyperlipidaemia
USFDA's final approval is available for Zydus Lifesciences and group companies, and this will allow the group to sell the product in the highly regulated US market.
The approval includes various strengths of Jaythari, 6 mg, 18 mg, 30 mg, and 36 mg, which adds to Zydus' portfolio of products in the US generic pharma market.
As per the company’s filing, this new subsidiary will be the vehicle through which Zydus plans to acquire the equity shares of Amplitude Surgical SA.
Here are some of the stocks that may see significant price movement today: GAIL, Zydus Lifesciences, Aurobindo Pharma, etc.
As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
